Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Anticancer Agent Lenvatinib Granted EMA Accelerated Review: Eisai
August 1, 2014
- Kyowa Kirin to Outsource Sales of Recombinant Human Antithrombin Preparation to JB
August 1, 2014
- Takara Bio to Buy Swedish Stem Cell Company
July 31, 2014
- Kyowa Kirin’s Half-Year Pharma Operating Profit Tumbles 41% on Price Cuts
July 31, 2014
- Nissan Chemical Files Livalo Patent Suit against Sawai in US
July 31, 2014
- Sanofi Files NDA for HOE901-U300, Successor Drug to Lantus, in Japan
July 31, 2014
- LSI Medience, Kyushu TLO Jointly Set Up KPSL, New Business Entity in Clinical Laboratory Test Field
July 31, 2014
- Kyowa Kirin Begins PI Study for XLH Adult Patients in Japan, South Korea
July 30, 2014
- Alfresa Group Companies Tokiwa Yakuhin and Seiwa Sangyo to Merge
July 30, 2014
- Meiji Seika Pharma Licenses Opalmon from Ono for Its Commercialization in Thailand and Indonesia
July 29, 2014
- AbbVie Hopes to Make Humira Major Drug for Biologics-Naïve Patients: President
July 28, 2014
- New Guidelines for Investigator-Led Trials to Take Effect at August-End: Novartis Japan
July 28, 2014
- Januvia Ranked No.1 in GP Market in June: Anterio’s “Mind Share” Ranking
July 28, 2014
- TS-1 Fails to Meet Primary Endpoint in PIII Study in Japan for Advanced Hepatocellular Carcinoma: Taiho
July 28, 2014
- Chugai Half-Year Earnings Upbeat on Actemra; Anti-PCSK9 Drug Ditched from Pipeline
July 25, 2014
- Kyowa Kirin Launches PII Study for XLH Drug KRN23 in US, Europe
July 25, 2014
- Sumitomo Dainippon, Taiho to Invest US$30 Million Each in Remiges BioPharma Fund
July 25, 2014
- Ono, BMS Announce Strategic Alliance for 5 Immuno-Oncology Products
July 25, 2014
- R-Tech Ueno Files for Orphan Drug Designation for Unoprostone Isopropyl for Retinitis Pigmentosa
July 25, 2014
- With Series of Antidiabetics on the Way, Prioritization Will Be a Challenge: Lilly Japan Diabetes Head
July 25, 2014
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…